NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36
Listen: PITTSBURGH, April 23, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused
Listen: PITTSBURGH, April 22, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing
Episode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,”
PITTSBURGH, February 6, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative
Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003 New York, January 07, 2024 –PRISM MediaWire – PRISM MarketView has released an
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 6, 2024 – PRISM MediaWire – Oncocyte
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
